MedTrace Logo

Early Interferon-beta Treatment for West-Nile Virus Infection

NCT06510426 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-07-23

No results posted yet for this study

Summary

West Nile virus (WNV) is a mosquito-borne virus which in majority of cases causes only self-limited disease.

Despite that, in minority of cases (\~0.5%) it can infect the brain and cause severe and even life-threatening disease (neuroinvasive disease).

Recent study has shown that up to 40% of WNV patients who develop neuroinvasive disease, have antibodies against Interferons (anti-Type I interferon autoantibodies), which neutralizes interferons, and could explain the development of severe disease.

The investigators therefore assume that early treatment with interferon beta (the type of interferon against which most patients do not have neutralizing antibodies) could prevent the development of severe neuroinvasive WNV disease.

Conditions

  • West Nile Virus
  • West Nile Fever Encephalitis
  • West Nile Fever Myelitis
  • West Nile Fever With Other Complications

Interventions

DRUG

Rebif 44 MCG Per 0.5 ML Prefilled Syringe

Rebif 44mcg per 0.5ml administered subcutaneously

DRUG

Saline

0.5mL of saline administered subcutaneously

Sponsors & Collaborators

  • Tel-Aviv Sourasky Medical Center

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-14
Primary Completion
2025-07-14
Completion
2025-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06510426 on ClinicalTrials.gov